MX9702357A - Spray-dried microparticles as therapeutic vehicles. - Google Patents

Spray-dried microparticles as therapeutic vehicles.

Info

Publication number
MX9702357A
MX9702357A MX9702357A MX9702357A MX9702357A MX 9702357 A MX9702357 A MX 9702357A MX 9702357 A MX9702357 A MX 9702357A MX 9702357 A MX9702357 A MX 9702357A MX 9702357 A MX9702357 A MX 9702357A
Authority
MX
Mexico
Prior art keywords
spray
dried microparticles
therapeutic
agent
therapeutic vehicles
Prior art date
Application number
MX9702357A
Other languages
Spanish (es)
Other versions
MXPA97002357A (en
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of MXPA97002357A publication Critical patent/MXPA97002357A/en
Publication of MX9702357A publication Critical patent/MX9702357A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e

Abstract

Microparticles of a water-soluble material, which are smooth and spherical, and at least 90 percent of which have a mass median particle size of 1 to 10 'mu'm, and which either carry a therapeutic or diagnostic agent or use such an agent as the water-soluble material, can successfully be used in dry powder inhalers to deliver the said agent.
MX9702357A 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles. MX9702357A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94307126 1994-09-29
EP94307126.6 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Publications (2)

Publication Number Publication Date
MXPA97002357A MXPA97002357A (en) 1997-06-01
MX9702357A true MX9702357A (en) 1997-06-28

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702357A MX9702357A (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles.

Country Status (16)

Country Link
EP (1) EP0783298A1 (en)
JP (1) JPH10506406A (en)
KR (1) KR970705979A (en)
AU (1) AU701440B2 (en)
BR (1) BR9509171A (en)
CA (1) CA2199954A1 (en)
CZ (1) CZ92497A3 (en)
FI (1) FI971332A (en)
HU (1) HUT77373A (en)
MX (1) MX9702357A (en)
NO (1) NO971438D0 (en)
NZ (1) NZ292980A (en)
PL (1) PL319600A1 (en)
RU (1) RU2147226C1 (en)
WO (1) WO1996009814A1 (en)
ZA (1) ZA958239B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
WO1997044015A1 (en) * 1996-05-17 1997-11-27 Andaris Limited Microparticles and their use in wound therapy
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB9615435D0 (en) * 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
WO1998017318A1 (en) * 1996-10-19 1998-04-30 Quadrant Healthcare (Uk) Limited Use of hollow microcapsules in diagnosis and therapy
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
AU5719798A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
PT954282E (en) * 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
ATE239447T1 (en) * 1997-09-29 2003-05-15 Inhale Therapeutic Syst STABILIZED PREPARATIONS USABLE IN NEBULIZERS
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
EP1056484A1 (en) * 1998-02-20 2000-12-06 Quadrant Healthcare (UK) Limited Products comprising fibrinogen for use in therapy
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
ES2198922T3 (en) * 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. LARGE POROUS PARTICLES ISSUED BY AN INHALER.
AU772798B2 (en) * 1999-04-21 2004-05-06 1355540 Ontario Inc. Formulations for detecting asthma
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
MXPA02006079A (en) 1999-12-20 2004-08-23 Nicholas J Kerkhof Process for producing nanometer particles by fluid bed spraydrying.
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
ATE355849T1 (en) * 2000-12-21 2007-03-15 Nektar Therapeutics STORAGE-Stable POWDER COMPOSITIONS WITH INTERLEUKIN-4 RECEPTOR
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
WO2003037303A1 (en) 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof
ATE508735T1 (en) 2001-12-19 2011-05-15 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1589901A4 (en) 2002-12-20 2006-08-09 Generipharm Inc Intracutaneous injection
AU2004251623B2 (en) 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
EP1646445A4 (en) 2003-07-18 2007-09-19 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
JP2010505883A (en) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド Compositions and methods for modulating immune responses
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
UA90013C2 (en) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
CA2738855A1 (en) 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (en) 2009-02-06 2010-08-11 ProFibrix BV Biodegradable extravascular support
ES2593584T3 (en) * 2009-05-28 2016-12-09 Profibrix Bv Dry powder fibrin sealant
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
KR20120125465A (en) 2010-01-08 2012-11-15 프로피브릭스 비.브이. Dry powder fibrin sealant
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
AU2011325857A1 (en) 2010-11-01 2013-05-02 University Of Technology, Sydney Immune-modulating agents and uses therefor
EP3225235B1 (en) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
CN105853348B (en) 2011-03-10 2019-08-30 Xeris药物公司 Parenteral injection stablizing solution
RU2013155713A (en) 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
KR102007057B1 (en) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. Formulations for the treatment of diabetes
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
US10350314B2 (en) * 2012-06-26 2019-07-16 Ge Healthcare As Preparation of composition comprising gas microbubbles
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9597339B2 (en) 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
WO2014124096A1 (en) 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2015054280A1 (en) 2013-10-08 2015-04-16 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP4218742A1 (en) 2014-04-04 2023-08-02 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
KR20170095807A (en) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 An inhalable rapamycin formulation for the treatment of pulmonary hypertension
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
EP3307295A1 (en) 2015-06-10 2018-04-18 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
TW201818933A (en) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 Compositions and methods for the treatment of neurodegenerative and other diseases
JP7299166B2 (en) 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド Precipitation-resistant small molecule drug formulation
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration

Also Published As

Publication number Publication date
HUT77373A (en) 1998-03-30
KR970705979A (en) 1997-11-03
AU701440B2 (en) 1999-01-28
CZ92497A3 (en) 1997-08-13
BR9509171A (en) 1997-09-16
EP0783298A1 (en) 1997-07-16
ZA958239B (en) 1996-09-30
PL319600A1 (en) 1997-08-18
CA2199954A1 (en) 1996-04-04
NZ292980A (en) 1999-02-25
WO1996009814A1 (en) 1996-04-04
AU3530295A (en) 1996-04-19
JPH10506406A (en) 1998-06-23
RU2147226C1 (en) 2000-04-10
FI971332A0 (en) 1997-04-01
NO971438L (en) 1997-03-26
FI971332A (en) 1997-04-01
NO971438D0 (en) 1997-03-26

Similar Documents

Publication Publication Date Title
MX9702357A (en) Spray-dried microparticles as therapeutic vehicles.
CA2012892A1 (en) Emulsifier-free hand and body lotion
EP0951917A3 (en) Particle delivery of particularly a powdered therapeutical agent
PL347640A1 (en) Dry powder for inhalation
GB9606677D0 (en) Process and device
MX9709448A (en) Methods and system for processing dispersible fine powders.
EP2258342A3 (en) Improvements in and relating to carrier particles for use in dry powder inhalers
WO2003024396A3 (en) Dry powder medicament formulations
WO2003105780A3 (en) A dry powder oligonucleotide formulation, preparation and its uses
EP1213012A3 (en) Improvements in and relating to powders for use in dry powder inhalers
FR2727689B1 (en)
WO2004019999A3 (en) Agent delivery particle
CA2304819A1 (en) Perforated microparticles and methods of use
TW280785B (en)
WO1996018388A3 (en) Cross-linked microparticles and their use as therapeutic vehicles
ZA935943B (en) New formulations
TW280780B (en)
NZ336592A (en) Formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml comprising finely divided budesonide and a carrier
CA2277890A1 (en) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
AR007493A1 (en) SPRAY DRIED MICROPARTICLES AS THERAPEUTIC VEHICLES FOR USE IN GENETIC THERAPY
ES2096521A1 (en) Microspheres of biodegradable synthetic polymers in the manufacture of reactive equipment for the preparation of radiopharmaceuticals.
GB9810806D0 (en) Odour absorbing agent
DE59803568D1 (en) Hautpflegemittel enthaltend hydroxycarbonsäurealkylester (cosmacol) und polymethacrylat copolymer (polytrap)
TH50858A (en) Powder cosmetic compound containing silicone elastomer
SG25394G (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein.